Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/Haybittle–Peto_boundary> ?p ?o }
Showing triples 1 to 25 of
25
with 100 triples per page.
- Haybittle–Peto_boundary abstract "The Haybittle–Peto boundary is a rule for deciding when to stop a clinical trial prematurely.The typical clinical trial compares two groups of patients. One group are given a placebo or conventional treatment, while the other group of patients are given the treatment that is being tested. The investigators running the clinical trial will wish to stop the trial early for ethical reasons if the treatment group clearly shows evidence of benefit. In other words, "when early results proved so promising it was no longer fair to keep patients on the older drugs for comparison, without giving them the opportunity to change."The Haybittle–Peto boundary is one such stopping rule, and it states that if an interim analysis shows a probability of less than 0.001 that the treatments are different, then the trial should be stopped early. The final analysis is still evaluated at the normal level of significance (usually 0.05). The main advantage of the Haybittle–Peto boundary is that the same threshold is used at every interim analysis, unlike other the O'Brien–Fleming boundary, which changes at every analysis. Also, using the Haybittle–Peto boundary means that the final analysis is performed using a 0.05 level of significance as normal, which makes it easier for investigators and readers to understand. The main argument against the Haybittle–Peto boundary is that some investigators believe that the Haybittle–Peto boundary is too conservative and makes it too difficult to stop a trial.".
- Haybittle–Peto_boundary wikiPageID "27629910".
- Haybittle–Peto_boundary wikiPageLength "3739".
- Haybittle–Peto_boundary wikiPageOutDegree "8".
- Haybittle–Peto_boundary wikiPageRevisionID "678853540".
- Haybittle–Peto_boundary wikiPageWikiLink Category:Clinical_research.
- Haybittle–Peto_boundary wikiPageWikiLink Category:Sequential_experiments.
- Haybittle–Peto_boundary wikiPageWikiLink Clinical_trial.
- Haybittle–Peto_boundary wikiPageWikiLink OBrienxe2x80x93Fleming_boundary.
- Haybittle–Peto_boundary wikiPageWikiLink Placebo.
- Haybittle–Peto_boundary wikiPageWikiLink Pocock_boundary.
- Haybittle–Peto_boundary wikiPageWikiLink Stopping_rule.
- Haybittle–Peto_boundary wikiPageWikiLink Stopping_time.
- Haybittle–Peto_boundary wikiPageWikiLinkText "Haybittle–Peto boundary".
- Haybittle–Peto_boundary hasPhotoCollection Haybittle–Peto_boundary.
- Haybittle–Peto_boundary wikiPageUsesTemplate Template:Reflist.
- Haybittle–Peto_boundary subject Category:Clinical_research.
- Haybittle–Peto_boundary subject Category:Sequential_experiments.
- Haybittle–Peto_boundary comment "The Haybittle–Peto boundary is a rule for deciding when to stop a clinical trial prematurely.The typical clinical trial compares two groups of patients. One group are given a placebo or conventional treatment, while the other group of patients are given the treatment that is being tested. The investigators running the clinical trial will wish to stop the trial early for ethical reasons if the treatment group clearly shows evidence of benefit.".
- Haybittle–Peto_boundary label "Haybittle–Peto boundary".
- Haybittle–Peto_boundary sameAs m.0c3yg6z.
- Haybittle–Peto_boundary sameAs Q5686201.
- Haybittle–Peto_boundary sameAs Q5686201.
- Haybittle–Peto_boundary wasDerivedFrom Haybittle–Peto_boundary?oldid=678853540.
- Haybittle–Peto_boundary isPrimaryTopicOf Haybittle–Peto_boundary.